Profusa (NASDAQ:PFSA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Profusa (NASDAQ:PFSA) to a sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings downgraded Profusa from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Profusa Price Performance

PFSA opened at $4.58 on Friday. The stock has a market capitalization of $2.79 million, a P/E ratio of -0.00 and a beta of 0.52. The company’s 50 day simple moving average is $9.10 and its 200-day simple moving average is $65.64. Profusa has a one year low of $3.22 and a one year high of $5,190.00.

Profusa (NASDAQ:PFSA) last issued its earnings results on Wednesday, August 19th. The company reported ($151.80) earnings per share (EPS) for the quarter.

Insider Transactions at Profusa

In related news, major shareholder Financial Lp Hrt sold 10,602 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $3.56, for a total transaction of $37,743.12. Following the completion of the sale, the insider directly owned 18,549 shares of the company’s stock, valued at approximately $66,034.44. This represents a 36.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders purchased 4,308 shares of company stock worth $16,594. 0.76% of the stock is currently owned by corporate insiders.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.